These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29333117)

  • 21. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
    Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B
    Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does Establishing a Safety Margin Reduce Local Recurrence in Subsegmental Transarterial Chemoembolization for Small Nodular Hepatocellular Carcinomas?
    Kang HJ; Kim YI; Kim HC; Jae HJ; Hur S; Chung JW
    Korean J Radiol; 2015; 16(5):1068-78. PubMed ID: 26357501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Occurrence of Vascular Lake Phenomenon Before Embolization for the Prediction of Lipiodol Uptake for Intermediate-Stage Hepatocellular Carcinoma Patients that Underwent cTACE.
    Hu B; Zhong BY; Zhang L; Dai C; Li W; Shen J; Huang P; Zhang S; Li Z; Ni CF
    Cardiovasc Intervent Radiol; 2020 Oct; 43(10):1460-1467. PubMed ID: 32500251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma.
    Jun CH; Ki HS; Lee HK; Park KJ; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS
    World J Gastroenterol; 2013 Jan; 19(2):284-9. PubMed ID: 23345952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Local Recurrence Between LEN-TACE and TACE for Hepatocellular Carcinoma According to Lipiodol Accumulation.
    Ishikawa T; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Cancer Diagn Progn; 2024; 4(5):611-616. PubMed ID: 39238622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization.
    Jin YJ; Chung YH; Kim JA; Park W; Lee D; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Kim PN; Sung KB
    Dig Dis Sci; 2013 Jun; 58(6):1758-65. PubMed ID: 23361574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Wang Z; Chen R; Duran R; Zhao Y; Yenokyan G; Chapiro J; Schernthaner R; Radaelli A; Lin M; Geschwind JF
    Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1548-56. PubMed ID: 26001366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
    Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
    Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
    Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response.
    Hu J; Maybody M; Cao G; Wang X; Chen H; Zhu X; Yang R; Wang X
    Cancer Imaging; 2016 Oct; 16(1):32. PubMed ID: 27716376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma.
    Kinugasa H; Nouso K; Takeuchi Y; Yasunaka T; Onishi H; Nakamura S; Shiraha H; Kuwaki K; Hagihara H; Ikeda F; Miyake Y; Takaki A; Yamamoto K
    J Gastroenterol; 2012 Apr; 47(4):421-6. PubMed ID: 22048256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
    Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
    Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
    He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M
    Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial.
    Vogl TJ; Langenbach MC; Hammerstingl R; Albrecht MH; Chatterjee AR; Gruber-Rouh T
    Hepatol Int; 2021 Jun; 15(3):685-694. PubMed ID: 34043158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma.
    Guiu B; Colin C; Cercueil JP; Loffroy R; Guiu S; Ferrant E; Jouve JL; Bonnetain F; Boulin M; Ghiringhelli F; Minello A; Hillon P; Bedenne L; Krause D; Chauffert B
    Am J Clin Oncol; 2009 Jun; 32(3):238-44. PubMed ID: 19349854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
    Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A retrospective study.
    Wang J; Shen JL
    Medicine (Baltimore); 2017 Dec; 96(52):e9236. PubMed ID: 29384909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.
    Savic LJ; Chapiro J; Funai E; Bousabarah K; Schobert IT; Isufi E; Geschwind JH; Stark S; He P; Rudek MA; Perez Lozada JC; Ayyagari R; Pollak J; Schlachter T
    Eur Radiol; 2021 May; 31(5):3002-3014. PubMed ID: 33063185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT).
    Yang P; Zeng ZC; Wang BL; Zhang JY; Fan J; Zhou J; Hu Y
    J Cancer; 2016; 7(11):1413-20. PubMed ID: 27471557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.